14,495 AbbVie Inc. $ABBV Shares Purchased by Artemis Investment Management LLP

Artemis Investment Management LLP raised its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.0% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 497,086 shares of the company’s stock after purchasing an additional 14,495 shares during the quarter. Artemis Investment Management LLP’s holdings in AbbVie were worth $130,033,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. State Street Corp increased its stake in AbbVie by 1.7% during the second quarter. State Street Corp now owns 82,596,748 shares of the company’s stock valued at $20,784,646,000 after purchasing an additional 1,379,232 shares during the last quarter. Corient Private Wealth LP acquired a new stake in shares of AbbVie during the second quarter worth $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new position in shares of AbbVie in the 2nd quarter valued at about $2,905,952,000. Finally, Deutsche Bank AG boosted its holdings in shares of AbbVie by 13.0% in the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after buying an additional 1,241,587 shares during the period. Institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: FDA breakthrough designations strengthen the oncology pipeline. The FDA granted two Breakthrough Therapy Designations for investigational telisotuzumab adizutecan (Temab-A/ABBV-400) in colorectal cancer and non-small cell lung cancer. The designations may accelerate development and regulatory discussions for the company’s next-generation antibody-drug conjugate. AbbVie Temab-A FDA breakthrough designations
• Positive Sentiment: Epkinly produced a significant Phase 3 result. AbbVie and Genmab reported that epcoritamab plus R-CHOP reduced the risk of progression or death by 51% versus R-CHOP alone in newly diagnosed diffuse large B-cell lymphoma. The data could support broader adoption and a stronger competitive position against Roche’s Polivy. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts remain constructive. Cantor Fitzgerald raised its AbbVie price target to $290 from $285 and maintained an overweight rating. HSBC has also outlined a bullish case with a $315 target, providing additional support for investor sentiment.
• Neutral Sentiment: Broader market factors may be limiting gains. Rising Treasury yields and uncertain equity-market conditions are creating pressure across stocks, even as healthcare companies benefit from defensive characteristics.
• Negative Sentiment: Dividend sustainability remains a concern. Recent commentary highlighted AbbVie’s reported payout ratio near 190%, raising questions about how comfortably earnings cover the dividend. The concern may weigh on income-focused investors, although adjusted earnings and cash flow can differ from reported net income.
• Negative Sentiment: Valuation leaves less room for disappointment. With ABBV trading near its 52-week high and at an elevated earnings multiple, investors may be taking profits or demanding stronger evidence that new medicines can offset long-term Humira-related pressures.

AbbVie Price Performance

Shares of NYSE ABBV traded down $2.33 during midday trading on Thursday, hitting $269.03. 1,665,149 shares of the company’s stock were exchanged, compared to its average volume of 6,408,634. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $274.94. The firm has a market cap of $475.31 billion, a P/E ratio of 76.02, a PEG ratio of 1.22 and a beta of 0.24. The stock’s 50 day moving average price is $258.27 and its 200-day moving average price is $235.87.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, beating the consensus estimate of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter in the previous year, the business earned $2.97 EPS. The firm’s revenue for the quarter was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, analysts expect that AbbVie Inc. will post 13.93 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s dividend payout ratio is presently 195.48%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ABBV. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and increased their price objective for the stock from $235.00 to $300.00 in a research note on Thursday, August 13th. Leerink Partners upped their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, August 4th. Sanford C. Bernstein reissued a “market perform” rating and issued a $225.00 price target (up from $203.00) on shares of AbbVie in a report on Tuesday, June 23rd. Finally, Oppenheimer upped their price objective on AbbVie from $244.00 to $258.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $276.11.

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 0.06% of the stock is owned by corporate insiders.

About AbbVie

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.